Poorer countries might soon have an easy access to cervical cancer vaccine, for two companies that manufacture the vaccine have promised to provide it at a reduced cost to these countries.
Cervical cancer rates are going up as more women than ever are surviving into middle age in poor countries.
Cervical Cancer - Incidence
Cervical cancer is the second most common cancer among women and is the primary cause of cancer-related deaths in developing countries
Advertisement
At a conference organised by the UN Development Fund for Women in Brussels, Belgium, last week, one of the companies, Merck, pledged to give enough vaccine to treat a million women in the poorest countries over the next five years.
A course of vaccine against the human papillomavirus (HPV), the cause of the majority of cases, is about 360 dollars in the US, reports New Scientist.
![New Cervical Cancer Vaccine Targets Women Over 30]( "New Cervical Cancer Vaccine Targets Women Over 30")
Gardasil, produced by US-based drug company Merck & Co, can only be administered to women up to the age of 26.
Out of the 250,000 women killed by cervical cancer annually, 80 per cent belong to poor nations. In developed countries, the screening to catch the cancer early has cut death rates.
The conference urged participants to develop more screening techniques in poor nations.
HPV is a sexually transmitted infection, and so the vaccine is targeted at young girls who are not yet sexually active.
Source: ANI
LIN/C
New Cervical Cancer Vaccine Targets Women Over 30
Gardasil, produced by US-based drug company Merck & Co, can only be administered to women up to the age of 26.
Advertisement
Out of the 250,000 women killed by cervical cancer annually, 80 per cent belong to poor nations. In developed countries, the screening to catch the cancer early has cut death rates.
The conference urged participants to develop more screening techniques in poor nations.
HPV is a sexually transmitted infection, and so the vaccine is targeted at young girls who are not yet sexually active.
Source: ANI
LIN/C
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.